ARHGEF6

Across TCGA pan-cancer cohorts, ARHGEF6 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ARHGEF6’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ARHGEF6 RNA is repressed in tumor relative to normal tissue. In most cancer types ARHGEF6 is over-expressed in tumor, although a few such as LUAD and COAD show the opposite, repressed pattern.

LUAD, KIRC, and COAD are the cancer types where ARHGEF6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−1.792	<.001	11	view →
KIRC	Male	All	+1.324	<.001	11	view →
COAD	Female	All	−1.000	<.001	10	view →
LUSC	Female	II,III,IV	−2.154	<.001	8	view →
BLCA	Male	III,IV	−1.470	<.001	8	view →
BRCA	All	III,IV	−1.647	<.001	6	view →
UCEC	All	All	−1.949	<.001	4	view →
KICH	All	All	+0.672	.002	4	view →
THCA	All	All	−0.407	.007	4	view →
READ	Female	All	−1.384	.024	2	view →
KIRP	All	IV	+1.227	.035	2	view →
HNSC	Male	All	−0.548	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ARHGEF6–LUAD

Open the LUAD breakdown →